189 related articles for article (PubMed ID: 22247448)
1. How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
Lewis RE; Lortholary O; Spellberg B; Roilides E; Kontoyiannis DP; Walsh TJ
Clin Infect Dis; 2012 Feb; 54 Suppl 1():S67-72. PubMed ID: 22247448
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
4. Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
Bellanger AP; Albert ND; Lewis RE; Walsh TJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2015 Dec; 59(12):7830-2. PubMed ID: 26392499
[TBL] [Abstract][Full Text] [Related]
5. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.
Chamilos G; Kontoyiannis DP
Drug Resist Updat; 2005 Dec; 8(6):344-58. PubMed ID: 16488654
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection.
Lewis RE; Liao G; Wang W; Prince RA; Kontoyiannis DP
Virulence; 2011; 2(4):348-55. PubMed ID: 21788730
[TBL] [Abstract][Full Text] [Related]
7. Future directions in mucormycosis research.
Kontoyiannis DP; Lewis RE; Lortholary O; Spellberg B; Petrikkos G; Roilides E; Ibrahim A; Walsh TJ
Clin Infect Dis; 2012 Feb; 54 Suppl 1(Suppl 1):S79-85. PubMed ID: 22247450
[TBL] [Abstract][Full Text] [Related]
8. Membrane and cell wall targets in Aspergillus fumigatus.
Beauvais A; Latgé JP
Drug Resist Updat; 2001 Feb; 4(1):38-49. PubMed ID: 11512152
[TBL] [Abstract][Full Text] [Related]
9. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
10. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors.
Xiong Q; Hassan SA; Wilson WK; Han XY; May GS; Tarrand JJ; Matsuda SP
Antimicrob Agents Chemother; 2005 Feb; 49(2):518-24. PubMed ID: 15673727
[TBL] [Abstract][Full Text] [Related]
12. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
14. Invasive fungal sinusitis in patients treated with fludarabine.
Todd T; Besser M; Gudgin E; Crawley C; Craig JI; Follows G; Marcus RE; Enoch DA; Cargill JS; Ludlam HA; Min SY; Sartori P
J Infect; 2008 Feb; 56(2):156-8. PubMed ID: 18155770
[No Abstract] [Full Text] [Related]
15. Posaconazole for treatment of refractory invasive fungal disease.
Notheis G; Tarani L; Costantino F; Jansson A; Rosenecker J; Friederici D; Belohradsky BH; Reinhardt D; Seger R; Schweinitz DV; Wintergerst U
Mycoses; 2006; 49 Suppl 1():37-41. PubMed ID: 16961581
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
[TBL] [Abstract][Full Text] [Related]
17. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
Guinea J; Peláez T; Alcalá L; Bouza E
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance in Aspergillus fumigatus.
Warris A; Weemaes CM; Verweij PE
N Engl J Med; 2002 Dec; 347(26):2173-4. PubMed ID: 12501236
[No Abstract] [Full Text] [Related]
20. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
